Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failure.
Heinz, D., Matthias, F., Andreas, Z., Alexander, N., Kurt, H., Juan, T., Dobromir, D., Arthur, M., & Stefan, A. (2026). Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failure.. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvag033
Heinz D, Matthias F, Andreas Z, Alexander N, Kurt H, Juan T, et al. Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failure.. Eur Heart J Cardiovasc Pharmacother. 2026; doi: 10.1093/ehjcvp/pvag033
Heinz D, Matthias F, Andreas Z, et al. Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failure.[J]. Eur Heart J Cardiovasc Pharmacother. 2026. DOI: 10.1093/ehjcvp/pvag033.
@article{heinz2026,
author = {Drexel Heinz and Frick Matthias and Zirlik Andreas and Niessner Alexander and Huber Kurt and Tamargo Juan and Dobrev Dobromir and Mader Arthur and Agewall Stefan},
title = {Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failure.},
journal = {Eur Heart J Cardiovasc Pharmacother},
year = {2026},
doi = {10.1093/ehjcvp/pvag033},
note = {PMID: 42097578},
}
TY - JOUR AU - Drexel Heinz AU - Frick Matthias AU - Zirlik Andreas AU - Niessner Alexander AU - Huber Kurt AU - Tamargo Juan AU - Dobrev Dobromir AU - Mader Arthur AU - Agewall Stefan TI - Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failure. T2 - Eur Heart J Cardiovasc Pharmacother PY - 2026 DO - 10.1093/ehjcvp/pvag033 AN - PMID:42097578 ER -
The combined prevalence of heart failure (HF) with coronary atherosclerosis is frequent and often causally linked. The aim of this review is to elucidate whether lipid lowering drugs (LLDs) are useful in this context. The role of LLDs is interesting in two ways: incidence of HF patients treated with LLD versus outcomes in patients with a history of HF. Rosuvastatin and alirocumab have been tested in outcome trials specifically on patients with HF, the results are neutral since no benefit arose. To the contrary, use of statins in individuals without HF at baseline has been demonstrated to weakly but significantly reduce the incidence of HF. Overall, there is no notion that statins or other LLD are harmful in patients with HF. We will discuss the contribution of systemic inflammation and consider ischaemic versus non-ischaemic HF. We conclude that in contrast to other comorbidities like e.g. type 2 diabetes mellitus (T2DM), in HF we face a below-than-average efficacy of LLDs in terms of reducing hard cardiovascular endpoints.